share_log

ティムス---急反発、TMS-008の第I相臨床試験における最初の被験者への投与実施

Tim's - Sharp rebound, the first administration of TMS-008 to subjects in Phase I clinical trials.

Fisco Japan ·  Jun 19 20:23

Rapid rebound. TMS-008, which has been developed as a candidate drug for acute kidney injury, announced that the first administration was carried out in the phase I clinical trial. Although the effectiveness and safety of TMS-008 in the non-clinical phase have been confirmed based on the results of previous non-clinical trials, in this trial, healthy adult men were gradually given TMS-008 for each cohort to confirm safety, tolerability and pharmacokinetics in humans. We plan to complete the administration and observation of all subjects within this fiscal year, and conduct the first lead-out in the first quarter of FY2025.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment